Senate Democrats seek to prohibit federal funding of legal attack on ACA

Senate Democrats aim to prevent the U.S. Justice Department from using federal money to support a lawsuit that seeks to invalidate the ACA, The Hill reports.

Advertisement

The lawmakers hope to accomplish this through an amendment to unrelated disaster legislation.

Senate Minority Leader Chuck Schumer, D-N.Y., said the amendment would “very simply prohibit the Department of Justice from using any funding to litigate the downfall of the [ACA] in the circuit court,” according to the report.

The news comes after the Justice Department announced March 25 that it supports a Texas judge’s ruling that the entire federal health law be invalidated.

The federal judge in December sided with the Republican-led states that brought the lawsuit, Texas v. United States. Plaintiffs in the case argue that the tax law signed by President Donald Trump in December 2017, which eliminated the law’s individual mandate penalties, made the mandate unconstitutional and the rest of the ACA invalid.

The Justice Department had previously said it wouldn’t defend major provisions of the ACA and argued that the act’s protections for people with preexisting conditions can’t be separated from the mandate and should be invalidated.

The case is pending before the U.S. Court of Appeals for the 5th Circuit.

 

More articles on legal and regulatory issues:
DOJ supports striking entire ACA: 5 things to know
8 latest healthcare industry lawsuits, settlements
MedStar will pay $35M to settle kickback allegations

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Legal & Regulatory Issues

Advertisement

Comments are closed.